Is sandostatin lar given once a month?

Is Sandostatin LAR given once a month?

Yes, Sandostatin LAR is designed for monthly dosing. Its long-acting formulation allows patients to receive an intramuscular injection every 28 to 30 days after an initial stabilization period.

How does Sandostatin LAR differ from immediate-release Sandostatin?

Immediate-release Sandostatin requires multiple daily injections or continuous subcutaneous infusion. Sandostatin LAR encapsulates octreotide in biodegradable microspheres, enabling gradual release over four weeks. This reduces injection burden and improves patient convenience.

What conditions warrant this monthly dosing schedule?

The monthly schedule applies to patients with acromegaly, carcinoid tumors, and vasoactive intestinal peptide-secreting tumors who have stabilized on immediate-release Sandostatin. Doctors prescribe it when patients show good response and tolerability to the short-acting form.

What happens if a patient misses a scheduled dose?

Missing a dose should be addressed by contacting the healthcare provider. Providers may reschedule the injection within a few days of the missed date or adjust the dose if multiple doses are missed. The 28-to-30-day window keeps blood levels consistent.

What side effects are patients most concerned about?

Patients often worry about injection-site reactions, gallstones, hyperglycemia, and gastrointestinal issues such as diarrhea, nausea, and abdominal pain. The monthly version shows similar profile to immediate-release Sandostatin except for localized pain at the injection site.

When does the Sandostatin LAR patent expire?

The primary compound patent expired long ago. Microsphere encapsulation technology patents expired in the 2000s. Current barriers to generic entry remain through regulatory data exclusivity and brand loyalty.